Bone marrow biopsy findings before and after ide-cel CAR-T therapy
| Characteristic . | Baseline (N = 52) . | Day 30 (N = 48) . | Day 90 (N = 37) . |
|---|---|---|---|
| Marrow cellularity – n (%) | |||
| Hypocellular | 12 (23%) | 19 (40%) | 18 (49%) |
| Normocellular | 19 (37%) | 16 (33%) | 8 (22%) |
| Hypercellular | 21 (40%) | 5 (10%) | 7 (19%) |
| Variable | 0 (0%) | 5 (10%) | 3 (8%) |
| Not evaluable | 0 (0%) | 3 (6%) | 1 (3%) |
| Marrow cellularity (%) – median (range) | 40 (2–99) | 25 (0–75) | 30 (5–95) |
| Not evaluable – n (%) | 0 (0%) | 1 (2%) | 1 (3%) |
| % CD138+by IHC – median (range) | 11.2 (0–100) | 0 (0–80) | 0 (0–80) |
| Not evaluable – n (%) | 0 (0%) | 2 (4%) | 0 (0%) |
| Fibrosis grade – median (range) | 0 (0–2) | 0 (0–3) | 0 (0–3) |
| Not evaluable – n (%) | 0 (0%) | 1 (2%) | 1 (3%) |
| Dysplasia present – n (%) | 1 (2%) | 1 (2%) | 0 (0%) |
| Not evaluable | 0 (0%) | 3 (6%) | 1 (3%) |
| Characteristic . | Baseline (N = 52) . | Day 30 (N = 48) . | Day 90 (N = 37) . |
|---|---|---|---|
| Marrow cellularity – n (%) | |||
| Hypocellular | 12 (23%) | 19 (40%) | 18 (49%) |
| Normocellular | 19 (37%) | 16 (33%) | 8 (22%) |
| Hypercellular | 21 (40%) | 5 (10%) | 7 (19%) |
| Variable | 0 (0%) | 5 (10%) | 3 (8%) |
| Not evaluable | 0 (0%) | 3 (6%) | 1 (3%) |
| Marrow cellularity (%) – median (range) | 40 (2–99) | 25 (0–75) | 30 (5–95) |
| Not evaluable – n (%) | 0 (0%) | 1 (2%) | 1 (3%) |
| % CD138+by IHC – median (range) | 11.2 (0–100) | 0 (0–80) | 0 (0–80) |
| Not evaluable – n (%) | 0 (0%) | 2 (4%) | 0 (0%) |
| Fibrosis grade – median (range) | 0 (0–2) | 0 (0–3) | 0 (0–3) |
| Not evaluable – n (%) | 0 (0%) | 1 (2%) | 1 (3%) |
| Dysplasia present – n (%) | 1 (2%) | 1 (2%) | 0 (0%) |
| Not evaluable | 0 (0%) | 3 (6%) | 1 (3%) |
Bone marrow biopsy findings at baseline, day 30, and day 90. Fibrosis was graded as 0 (none), 1 (mild), 2 (moderate), or 3 (marked). At day 30, 1 patient had died, and 3 patients did not undergo bone marrow biopsy. At day 90, 2 total patients had died, 3 patients progressed prior to day 90, and 10 patients did not undergo bone marrow biopsy. ide-cel, idecabtagene vicleucel; IHC, immunohistochemistry.